MedPath

山东安信制药有限公司

Ownership
-
Established
2019-09-02
Employees
-
Market Cap
-
Website
https://www.qilu-anxin.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

26

NMPA:26

Drug Approvals

Escitalopram Oxalate

Product Name
草酸艾司西酞普兰
Approval Number
国药准字H20173387
Approval Date
Apr 18, 2024
NMPA

Uracil

Product Name
尿嘧啶
Approval Number
国药准字H37023945
Approval Date
Apr 18, 2024
NMPA

Carmofur

Product Name
卡莫氟
Approval Number
国药准字H10970059
Approval Date
Apr 10, 2024
NMPA

Ampicillin Sodium

Product Name
氨苄西林钠
Approval Number
国药准字H37021337
Approval Date
Apr 10, 2024
NMPA

Capecitabine

Product Name
卡培他滨
Approval Number
国药准字H20123412
Approval Date
Aug 17, 2022
NMPA

Piperacillin

Product Name
哌拉西林
Approval Number
国药准字H20163397
Approval Date
Aug 13, 2021
NMPA

Piperacillin Sodium and Tazobactam Sodium for Injection

Product Name
邦达
Approval Number
国药准字H20123402
Approval Date
May 20, 2020
NMPA

Piperacillin Sodium and Tazobactam Sodium for Injection

Product Name
注射用哌拉西林钠他唑巴坦钠
Approval Number
国药准字H20133354
Approval Date
Mar 25, 2020
NMPA

Piperacillin Sodium and Tazobactam Sodium for Injection

Product Name
注射用哌拉西林钠他唑巴坦钠
Approval Number
国药准字H20133353
Approval Date
Mar 25, 2020
NMPA

Piperacillin Sodium and Tazobactam Sodium for Injection

Product Name
邦达
Approval Number
国药准字H19990181
Approval Date
Mar 25, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.